U01 Research Project Cooperative Agreement
Limited Competition: Continuation of the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study (U01)
The purpose of this Funding Opportunity Announcement (FOA) is to continue follow-up of the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) cohort through a cooperative agreement. TODAY was a multi-center controlled clinical trial examining the efficacy of three approaches to treat recently diagnosed type 2 diabetes in youth ages 10-17 years. TODAY demonstrated that combination therapy with metformin plus rosiglitazone sustained glycemic control longer than either metformin plus an intensive lifestyle program or metformin alone. TODAY study results also suggest that type 2 diabetes is more aggressive when it occurs at a young age. The primary purpose of this FOA is to continue follow-up of the TODAY cohort to define the long-term clinical course of youth-onset type 2 diabetes.
|Notice(s) for this Opportunity|
|Letter of Intent Due Date|
May 19, 2014
|Application Due Date|
June 19, 2014, by 5:00 PM local time of applicant organization.